The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.

Regeneron will provide the ETI with access to VelocImmune technology and potential financial support to use the company’s proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

ETI will undertake preclinical research and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.

Developed by Regeneron scientists, VelocImmune is a genetic engineering platform that enables the fast and efficient creation of superior fully-human monoclonal antibodies for drug development.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account